Introduction
============

The World Health Organization reported that 466 million people worldwide suffers from hearing loss and estimated to rise over 900 million by 2050 \[[@b1-gi-2018-16-4-e20]\]. Hearing loss means not able to hear as well as someone with normal hearing or a hearing threshold of more than 25 decibels in one or both ears. Hearing loss can also be classified as either conductive, sensorineural or mixed hearing loss. Conductive hearing loss is when there is a problem conducting the sound waves along the outer ear, tympanic membrane (eardrum) and ossicular chain of the middle ear towards the cochlea. Sensorineural hearing loss (SNHL) is when there is problem translating the sound vibrations into electrical signals in the sensory hair cells (HCs) inside the cochlear or damage in transmitting the information involving the afferent nerves towards the brain. This communication between the ear and brain can be damaged by aging, acoustic overexposure and ototoxic drugs. Heredity also plays a big part wherein genes for hearing are mutated or genes may increase the susceptibility to ear damage or deterioration from aging.

Hearing loss causes an annual global deficit of US \$750 billion \[[@b2-gi-2018-16-4-e20]\] which offers a high demand for an effective solution. Conductive hearing loss can be surgically managed in most patients. In contrast, SNHL is mostly irreversible and results in permanent hearing loss. However, hearing rehabilitation is possible thru hearing devices that can either be worn externally or implanted. Despite the advances in hearing aid and cochlear implant technologies, the quality of perceived sound still cannot mimic that of the normal ear. Impaired speech perception in noisy environments and musical sound perception are the biggest hurdles of cochlear implants \[[@b3-gi-2018-16-4-e20], [@b4-gi-2018-16-4-e20]\].

Scientist around the world are working on genomics-based research and development in hearing science. In this review, we consolidated the genes that are currently identified to be associated with hearing loss. We reviewed ways in which genes are used to restore or protect hearing and ways to deliver the genes to their target cells such as viral and non-viral vectors. We also discussed the various strategies used in gene therapy such as gene replacement, slicing and editing.

Genetic Hearing Loss
====================

Syndromic vs. nonsyndromic hearing loss
---------------------------------------

Clinically, hearing impairment may be associated with other disorders (syndromic) or it may only be a symptom (nonsyndromic). Syndromic hearing loss occurs with malformations of the external ear, together with other malformations in other organs or organ systems. Nonsyndromic hearing loss has no associated visible deformities or the external ear or any related medical conditions, but could be associated with problems of the middle or inner ear.

Deafness genes
--------------

Genes are responsible for hearing loss among 50%--60% of children born with hearing loss \[[@b5-gi-2018-16-4-e20]\]. According to the Hereditary Hearing Loss Homepage \[[@b6-gi-2018-16-4-e20]\] to date, there is a total of 112 non-syndromic hearing loss genes that has been identified ([Fig. 1](#f1-gi-2018-16-4-e20){ref-type="fig"}), 71 autosomal recessive ([Table 1](#t1-gi-2018-16-4-e20){ref-type="table"}) \[[@b7-gi-2018-16-4-e20]--[@b125-gi-2018-16-4-e20]\], 45 autosomal dominant ([Table 2](#t2-gi-2018-16-4-e20){ref-type="table"}) \[[@b126-gi-2018-16-4-e20]--[@b207-gi-2018-16-4-e20]\], and 5 X-linked and 1 non-syndromic genes ([Table 3](#t3-gi-2018-16-4-e20){ref-type="table"}) \[[@b208-gi-2018-16-4-e20]--[@b218-gi-2018-16-4-e20]\]. The most common cause of severe-to-profound nonsyndromic hearing loss in most populations is the autosomal recessive mutation of *GJB2*. While the most common cause of mild-to-moderate hearing loss is the autosomal recessive mutation on *STRC* \[[@b219-gi-2018-16-4-e20]\]. On the other hand, About 30% of inherited hearing loss is associated with a syndrome \[[@b220-gi-2018-16-4-e20]\]. Syndromic hearing impairment tends to be less genetically heterogeneous than nonsyndromic, but more than one locus has been identified for several syndromes. There are currently 11 syndromes ([Table 4](#t4-gi-2018-16-4-e20){ref-type="table"}) \[[@b221-gi-2018-16-4-e20]--[@b265-gi-2018-16-4-e20]\] associated with hearing loss with a total of 47 syndromic hearing loss genes with 27 autosomal recessive, 13 autosomal dominant, 4 autosomal dominant or recessive and 2 X-linked recessive pattern of inheritance.

Relevance of genomics in hearing loss
-------------------------------------

With the rapid advancement of genomics, it became possible to establish high-resolution genetic and physical maps, genomic and cDNA libraries which made it easier to correlate the genes for hearing loss. The establishment of the human fetal cochlear cDNA library gave way to the cloning of majority of the genes identified related to hearing loss \[[@b266-gi-2018-16-4-e20]\]. Screening strategies can be made in combination with next-generation sequencing platforms to study sets of deafness subjects who are likely to have the same defective gene to effectively diagnose patients with genetic hearing loss \[[@b267-gi-2018-16-4-e20]\].

Gene Therapy
------------

As mentioned above, genetic hearing loss can now be screened *in utero*. In principle, gene therapy can fix a genetic mutation like the ones involving hearing genes removing or replacing the defective gene or supplying the absent gene.

However, compared to other target organs for gene therapy, there are several obstacles related to the anatomy of the inner ear. The cochlea is a spiraled and fluid-filled cavity in a bony labyrinth that is very vulnerable to changes which affect the conversion of sound vibration into electrical signals. Consequently, maintaining this homeostasis is the biggest challenge in delivering any kind of therapeutic products into the inner ear. Different routes of administration have been explored with various purposes, such as efficiency in transduction and reduced cochlear toxicity. The most successful way to deliver therapeutic agents to the cochlea is an intracochlear approach through the round window membrane (RWM). The RWM is a semipermeable soft tissue separating the middle and inner ear. It allows low molecular weight molecules to up to molecules with molecular weight 45,000 under normal physiological conditions \[[@b268-gi-2018-16-4-e20]\]. Direct injection through the RWM can also be done with a microsyringe and a narrow-gauge needle. Another option is to insert material inside the cochlear cavity to create an opening, in a procedure called a cochleostomy. This was the approach used by our group to inject material into the three cochlear cavities (scala vestibule, scala media, and scala tympani) \[[@b269-gi-2018-16-4-e20], [@b270-gi-2018-16-4-e20]\].

Viral vs. non-viral gene delivery
---------------------------------

Gene transfection to inner ear cells have mostly utilized replication defective viral vectors ([Table 5](#t5-gi-2018-16-4-e20){ref-type="table"}) \[[@b274-gi-2018-16-4-e20]--[@b280-gi-2018-16-4-e20]\]. For example, adenoviruses were used to transfer gene markers such as *β*-galactosidase and red fluorescent protein as well as functional genes such as glial-derived neurotrophic factor (*GDNF*) to the auditory system \[[@b270-gi-2018-16-4-e20], [@b281-gi-2018-16-4-e20], [@b282-gi-2018-16-4-e20]\]. Another example is the use of adeno-associated viral vectors (AAV), such as AAV1, 2, 6, 8, and Anc80L65, which showed greater transfection efficiency in inner ear delivery \[[@b283-gi-2018-16-4-e20]\]. Recently, the USH1 protein network component harmonin (*USH1C*) gene delivery using synthetic Anc80L65 vectors to treat hearing loss in mice with Usher syndrome restored complex auditory and balance behaviour similar to near wild-type levels with up to 90% transduction efficiency \[[@b276-gi-2018-16-4-e20]\]. AAV2/8 vectors that encode wild-type whirlin (*WHRN*) gene restored inner hair cells (IHC) but not outer hair cells (OHC) and auditory function \[[@b272-gi-2018-16-4-e20]\]. AAV2/1 vectors were injected in transmembrane channel like 1 (*TMC1*) mutant mice restored moderate hearing function with minimal auditory-brainstem-response threshold \[[@b284-gi-2018-16-4-e20]\]. A similar viral capsid and a promoter that restricted expression to IHCs partially restored auditory function in mice deficient in the IHC gene encoding for vesicular glutamate transporter 3 (VGluT3) \[[@b271-gi-2018-16-4-e20]\]. Furthermore, the cellular tropism of a novel adeno-associated bovine virus vector efficiently transduced cochlear and vestibular HC and supporting cells without pathological effects outperforming other viral vectors \[[@b285-gi-2018-16-4-e20]\].

The concept of gene therapy seems straightforward, but numerous problems and risks exist that prevent gene therapy using viral vectors \[[@b286-gi-2018-16-4-e20]\]. Even with all the potential benefits of gene therapy, the utilization of viral vectors in the clinical setup is hindered by the possibility of tumorigenesis and unexpected adverse effects from virus integration in human DNA. Therefore, non-viral delivery systems are developed as an alternative to harness gene therapy. These non-viral vectors include cationic liposomes and other non-liposomal polymers along with the use of biolistic materials and electroporation ([Table 6](#t6-gi-2018-16-4-e20){ref-type="table"}) \[[@b287-gi-2018-16-4-e20]--[@b301-gi-2018-16-4-e20]\].

Cationic liposomes are phospholipid vesicles that fuses to the cellular membrane due to their cationic charge, thereby releasing the DNA to the cytoplasm \[[@b302-gi-2018-16-4-e20]\]. Cationic liposomes can be easily prepared in large amounts, non-infectious and has a large gene capacity. Meanwhile, synthetic and naturally occurring polycationic polymers attract negatively charged phosphates of the DNA \[[@b303-gi-2018-16-4-e20]\]. These include polyethylenimine, dextran, chitosan, PLGA and among others. Cationic polymers are also easy to prepare and non-immunogenic. However, both types have low transfection yields and may still provoke an acute immune response.

Another mode of gene transfection makes use of DNA-coated gold microparticles and bombarded into a targeted cellular surface by a pressure pulse of compressed helium gas \[[@b304-gi-2018-16-4-e20]\]. These are not immunogenic and results in a very good *in vivo* activity. Electroporation is also used to create transient pores in the lipid membrane, allowing the transfection of plasmid DNA, using electric field pulses \[[@b305-gi-2018-16-4-e20]\]. However, these methods may cause significant tissue damage during the procedure and need surgery for targeted internal organs. Gene transfer is also limited to the targeted area only.

Gene therapy strategies
-----------------------

### Gene replacement using cDNA

Gene replacement is basically delivering a functional cDNA with the correct coding sequence to supplement a nonfunctional mutant gene of interest in specific cell types \[[@b306-gi-2018-16-4-e20]\]. The ideal application of gene replacement is in genetic disorders caused by mutations leading to loss in phenotype, such as recessive diseases. However, effectivity of this gene therapy is limited by the duration in which gene is delivered during development of target organs. If the mutation begins during prenatal development, gene replacement may not be able to recover normal physiology after significant malformations. In addition, an extended expression of the exogenous sequence must be maintained if the mutated gene is expressed into adulthood. Dominant deafness mutations are less likely to be recovered with gene replacement strategies but other approaches can still be utilized.

### Gene silencing using RNA interference

Dominant hearing loss mutations in heterozygous animals can be "silenced" or negatively regulated by suppressing the mutant allele while allowing expression of the wild-type allele to overcome the consequences of the mutation. Gene silencing can be achieved at the transcriptional level by preventing the mRNA from being transcribed. At the post-transcriptional level, gene silencing occurs with use of RNA interference (RNAi) to prevent mRNA translation \[[@b307-gi-2018-16-4-e20]\]. The central role in RNAi is played by two types of short complementary small RNA---microRNA (miRNA) or small interfering RNA (siRNA). In an acoustic overexposure study in mouse, siRNA was found to be able to silence the expression of AMP-activated protein kinase which causes HC loss and cochlear synaptopathy \[[@b308-gi-2018-16-4-e20]\]. The main advantage of this method its sequence specificity which makes it very suitable for silencing dominant mutations without affecting wild-type sequences or off target sequences \[[@b309-gi-2018-16-4-e20]\].

### Gene editing using CRISPR/Cas9 system

Another gene therapy approach that recently gained much attention to edit genome sequences is the use of the CRISPE/Cas9 system. This approach is derived from prokaryotic immune systems for resistance to phages and plasmids \[[@b310-gi-2018-16-4-e20]\]. It is the most recent and advanced programmable nuclease adapted for genome engineering which allows for the precise direct manipulation of genome sequences in the inner ear \[[@b311-gi-2018-16-4-e20]\]. Engineered nuclease-based enzymes are used to find a target genome sequence and to introduce single- or double-strand DNA, which stimulate innate DNA repairing machinery.

CRISPR/Cas is considered as the most pervasive and easy-to-use system with multiple applications. Cas9 require the presence of a protospacer adjacent motif (PAM) immediately following the DNA target sequence which enables the system to be very specific but at the same time limits its clinical application \[[@b312-gi-2018-16-4-e20]\]. To date, much effort has been directed toward the design of CRIPSR nucleases with altered PAM specificities and diminished off target activities allowing even more applications \[[@b313-gi-2018-16-4-e20]\].

Clinical Application and Conclusions
====================================

Gene therapy is making a comeback after safety concerns during the late 1990s and early 2000s hampered research. Gene therapy for genetic hearing loss is also getting one step closer into being a clinical treatment after several clinical trials have been approved but yet to bear results. Although gene therapy is a promising treatment option, its application is currently limited by the risk of side effects and is still under study to ensure that it will be safe and effective. In the meantime, there are 2,597 clinical trials undertaken in 38 countries that have been either completed, are in progress, or approved involving gene therapy \[[@b314-gi-2018-16-4-e20]\]. As we wait for preliminary results to ongoing clinical trials for gene therapy for hearing loss, there are already several syndromic hearing loss genes mentioned above wherein gene therapy trials have begun for their corresponding syndromes. These include the autosomal recessive gene *MYO7A* causing deaf-blindness in Usher syndrome \[[@b315-gi-2018-16-4-e20]\]. Furthermore, lessons from different approaches in gene therapy in other systems can greatly influence the advancement in design and implementation of gene therapy for genetic hearing loss. Additional advances are expected in the coming years as the field of inner gene therapy moves toward the collective goal of developing novel and effective treatments for patients with genetic hearing loss.
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###### 

Autosomal recessive non-syndromic hearing loss genes and loci according to Hereditary Hearing Loss Homepage \[[@b6-gi-2018-16-4-e20]\]

  Locus (OMIM)          Location          Gene (OMIM)       Key references (PubMed)
  --------------------- ----------------- ----------------- --------------------------------------------------------
  DFNB1A                13q12             *GJB2*            \[[@b7-gi-2018-16-4-e20], [@b8-gi-2018-16-4-e20]\]
  DFNB1B                13q12             *GJB6*            \[[@b9-gi-2018-16-4-e20]\]
  DFNB2                 11q13.5           *MYO7A*           \[[@b10-gi-2018-16-4-e20]--[@b12-gi-2018-16-4-e20]\]
  DFNB3                 17p11.2           *MYO15A*          \[[@b13-gi-2018-16-4-e20], [@b14-gi-2018-16-4-e20]\]
  DFNB4                 7q31              *SLC26A4*         \[[@b15-gi-2018-16-4-e20], [@b16-gi-2018-16-4-e20]\]
  DFNB5 (see note 1)    14q12             Unknown           \[[@b17-gi-2018-16-4-e20]\]
  DFNB6                 3p14 p21          *TMIE*            \[[@b18-gi-2018-16-4-e20], [@b19-gi-2018-16-4-e20]\]
  DFNB7/11              9q13 q21          *TMC1*            \[[@b20-gi-2018-16-4-e20]--[@b22-gi-2018-16-4-e20]\]
  DFNB8/10              21q22             *TMPRSS3*         \[[@b23-gi-2018-16-4-e20]--[@b25-gi-2018-16-4-e20]\]
  DFNB9 (see note 2)    2p22-p23          *OTOF*            \[[@b26-gi-2018-16-4-e20], [@b27-gi-2018-16-4-e20]\]
  DFNB10                See DFNB8         \-                \-
  DFNB11                See DFNB7         \-                \-
  DFNB12                10q21 q22         *CDH23*           \[[@b28-gi-2018-16-4-e20], [@b29-gi-2018-16-4-e20]\]
  DFNB13                7q34 36           Unknown           \[[@b30-gi-2018-16-4-e20]\]
  DFNB14                7q31              Unknown           \[[@b31-gi-2018-16-4-e20]\]
  DFNB15/72/95          3q21 q25,19p13    *GIPC3*           \[[@b32-gi-2018-16-4-e20]--[@b34-gi-2018-16-4-e20]\]
  DFNB16                15q21 q22         *STRC*            \[[@b35-gi-2018-16-4-e20]\]
  DFNB17                7q31              Unknown           \[[@b36-gi-2018-16-4-e20]\]
  DFNB18                11p14 15.1        *USH1C*           \[[@b37-gi-2018-16-4-e20]--[@b39-gi-2018-16-4-e20]\]
  DFNB18B               11p15.1           *OTOG*            \[[@b40-gi-2018-16-4-e20]\]
  DFNB19                18p11             Unknown           \[[@b41-gi-2018-16-4-e20]\]
  DFNB20                11q25-qter        Unknown           \[[@b42-gi-2018-16-4-e20]\]
  DFNB21                11q               *TECTA*           \[[@b43-gi-2018-16-4-e20]\]
  DFNB22                16p12.2           *OTOA*            \[[@b44-gi-2018-16-4-e20]\]
  DFNB23                10p11.2 q21       *PCDH15*          \[[@b45-gi-2018-16-4-e20]\]
  DFNB24                11q23             *RDX*             \[[@b46-gi-2018-16-4-e20]\]
  DFNB25                4p13              *GRXCR1*          \[[@b47-gi-2018-16-4-e20]\]
  DFNB26 (see note 3)   4q31              Unknown           \[[@b48-gi-2018-16-4-e20]\]
  DFNB27                2q23 q31          Unknown           \[[@b49-gi-2018-16-4-e20]\]
  DFNB28                22q13             *TRIOBP*          \[[@b50-gi-2018-16-4-e20], [@b51-gi-2018-16-4-e20]\]
  DFNB29                21q22             *CLDN14*          \[[@b52-gi-2018-16-4-e20]\]
  DFNB30                10p11.1           *MYO3A*           \[[@b53-gi-2018-16-4-e20]\]
  DFNB31                9q32 q34          *WHRN*            \[[@b54-gi-2018-16-4-e20], [@b55-gi-2018-16-4-e20]\]
  DFNB32/105            1p13.3 22.1       *CDC14A*          \[[@b56-gi-2018-16-4-e20], [@b57-gi-2018-16-4-e20]\]
  DFNB33                9q34.3            Unknown           \[[@b58-gi-2018-16-4-e20]\]
  DFNB35                14q24.1 24.3      *ESRRB*           \[[@b59-gi-2018-16-4-e20], [@b60-gi-2018-16-4-e20]\]
  DFNB36                1p36.3            *ESPN*            \[[@b61-gi-2018-16-4-e20]\]
  DFNB37                6q13              *MYO6*            \[[@b62-gi-2018-16-4-e20]\]
  DFNB38                6q26 q27          Unknown           \[[@b63-gi-2018-16-4-e20]\]
  DFNB39                7q21.1            *HGF*             \[[@b64-gi-2018-16-4-e20]\]
  DFNB40                22q               Unknown           \[[@b65-gi-2018-16-4-e20]\]
  DFNB42                3q13.31 q22.3     *ILDR1*           \[[@b66-gi-2018-16-4-e20], [@b67-gi-2018-16-4-e20]\]
  DFNB44                7p14.1 q11.22     *ADCY1*           \[[@b68-gi-2018-16-4-e20], [@b69-gi-2018-16-4-e20]\]
  DFNB45                1q43 q44          Unknown           \[[@b70-gi-2018-16-4-e20]\]
  DFNB46                18p11.32 p11.31   Unknown           \[[@b71-gi-2018-16-4-e20]\]
  DFNB47                2p25.1 p24.3      Unknown           \[[@b72-gi-2018-16-4-e20]\]
  DFNB48                15q23 q25.1       *CIB2*            \[[@b73-gi-2018-16-4-e20]\]
  DFNB49                5q12.3 q14.1.     *MARVELD2/BDP1*   \[[@b74-gi-2018-16-4-e20]--[@b76-gi-2018-16-4-e20]\]
  DFNB51                11p13 p12         Unknown           \[[@b77-gi-2018-16-4-e20]\]
  DFNB53                6p21.3            *COL11A2*         \[[@b78-gi-2018-16-4-e20]\]
  DFNB55                4q12 q13.2        Unknown           \[[@b79-gi-2018-16-4-e20]\]
  DFNB59                2q31.1 q31.3      PJVK              \[[@b80-gi-2018-16-4-e20]\]
  DFNB60                5q23.2 q31.1      *SLC22A4*         \[[@b81-gi-2018-16-4-e20]\]
  DFNB61                7q22.1            *SLC26A5*         \[[@b82-gi-2018-16-4-e20]\]
  DFNB62                12p13.2 p11.23    Unknown           \[[@b83-gi-2018-16-4-e20]\]
  DFNB63                11q13.2 q13.4     *LRTOMT/COMT2*    \[[@b84-gi-2018-16-4-e20], [@b85-gi-2018-16-4-e20]\]
  DFNB65                20q13.2 q13.32    Unknown           \[[@b86-gi-2018-16-4-e20]\]
  DFNB66                6p21.2 22.3       *DCDC2*           \[[@b87-gi-2018-16-4-e20]\]
  DFNB66/67             6p21.31           *LHFPL5*          \[[@b88-gi-2018-16-4-e20]--[@b90-gi-2018-16-4-e20]\]
  DFNB68                19p13.2           *S1PR2*           \[[@b91-gi-2018-16-4-e20], [@b92-gi-2018-16-4-e20]\]
  DFNB71                8p2221.3          Unknown           \[[@b93-gi-2018-16-4-e20]\]
  DFNB72                See DFNB15        \-                \-
  DFNB73                1p32.3            *BSND*            \[[@b94-gi-2018-16-4-e20]\]
  DFNB74                12q14.2 q15       *MSRB3*           \[[@b95-gi-2018-16-4-e20], [@b96-gi-2018-16-4-e20]\]
  DFNB76                19q13.12          *SYNE4*           \[[@b97-gi-2018-16-4-e20]\]
  DFNB77                18q12q 21         *LOXHD1*          \[[@b98-gi-2018-16-4-e20]\]
  DFNB79                9q34.3            *TPRN*            \[[@b99-gi-2018-16-4-e20]\]
  DFNB80                2p16.1 p21        Unknown           \[[@b100-gi-2018-16-4-e20]\]
  DFNB81                19p               Unknown           \[[@b34-gi-2018-16-4-e20]\]
  DFNB82                1p13.1            (see note 4)      \[[@b101-gi-2018-16-4-e20]\]
  DFNB83                See DFNA47        \-                \-
  DFNB84                12q21.2           *PTPRQ/OTOGL*     \[[@b102-gi-2018-16-4-e20], [@b103-gi-2018-16-4-e20]\]
  DFNB85                17p12 q11.2       Unknown           \[[@b101-gi-2018-16-4-e20]\]
  DFNB86                16p13.3           *TBC1D24*         \[[@b104-gi-2018-16-4-e20], [@b105-gi-2018-16-4-e20]\]
  DFNB88                2p12 p11.2        *ELMOD3*          \[[@b106-gi-2018-16-4-e20]\]
  DFNB89                16q21 q23.2       *KARS*            \[[@b107-gi-2018-16-4-e20]\]
  DFNB90                7p22.1 p15.3      Unknown           \[[@b108-gi-2018-16-4-e20]\]
  DFNB91                6p25              *SERPINB6*        \[[@b109-gi-2018-16-4-e20]\]
  DFNB93                11q12.311 q13.2   *CABP2*           \[[@b110-gi-2018-16-4-e20]\]
  DFNB94                \-                *NARS2*           \[[@b111-gi-2018-16-4-e20]\]
  DFNB95                See DFNB15        \-                \-
  DFNB96                1p36.31 p36.13    Unknown           \[[@b112-gi-2018-16-4-e20]\]
  DFNB97                7q31.2q31.31      *MET*             \[[@b113-gi-2018-16-4-e20]\]
  DFNB98                21q22.3-qter      *TSPEAR*          \[[@b114-gi-2018-16-4-e20]\]
  DFNB99                17q12             *TMEM132E*        \[[@b115-gi-2018-16-4-e20]\]
  DFNB100               5q13.2 q23.2      *PPIP5K2*         \[[@b116-gi-2018-16-4-e20]\]
  DFNB101               5q32              *GRXCR2*          \[[@b117-gi-2018-16-4-e20]\]
  DFNB102               12p12.3           *EPS8*            \[[@b118-gi-2018-16-4-e20]\]
  DFNB103               6p21.1            *CLIC5*           \[[@b119-gi-2018-16-4-e20]\]
  DFNB104               6p22.3            *FAM65B*          \[[@b120-gi-2018-16-4-e20]\]
  DFNB105               See DFNB32        \-                \[[@b57-gi-2018-16-4-e20]\]
  DFNB106               11p15.5           *EPS8L2*          \[[@b121-gi-2018-16-4-e20]\]
  DFNB108               1p31.3            *ROR1*            \[[@b122-gi-2018-16-4-e20]\]

Note 1: DFNB5 was reported originally as DFNB4.

Note 2: DFNB9 was reported originally as DFNB6.

Note 3: DFNB26 is suppressed by dominant modifier DFNM1.

Note 4: The gene at the DFNB82 locus was initially reported as GPSM2 \[[@b123-gi-2018-16-4-e20]\], but this gene was later determined to cause Chudley-McCullough syndrome \[[@b124-gi-2018-16-4-e20], [@b125-gi-2018-16-4-e20]\].

###### 

Autosomal dominant non-syndromic hearing loss genes and loci according to Hereditary Hearing Loss Homepage \[[@b6-gi-2018-16-4-e20]\]

  Locus (OMIM)          Location          Gene (OMIM)     Key references (PubMed)
  --------------------- ----------------- --------------- --------------------------------------------------------------------------------
  DFNA1                 5q31              *DIAPH1*        \[[@b126-gi-2018-16-4-e20], [@b127-gi-2018-16-4-e20]\]
  DFNA2A                1p34              *KCNQ4*         \[[@b129-gi-2018-16-4-e20], [@b130-gi-2018-16-4-e20]\]
  DFNA2B                1p35.1            *GJB3*          \[[@b132-gi-2018-16-4-e20]\]
  DFNA2C                \-                *IFNLR1*        \[[@b134-gi-2018-16-4-e20]\]
  DFNA3A                13q11 q12         *GJB2*          \[[@b8-gi-2018-16-4-e20], [@b135-gi-2018-16-4-e20], [@b136-gi-2018-16-4-e20]\]
  DFNA3B                13q12             *GJB6*          \[[@b138-gi-2018-16-4-e20]\]
  DFNA4A                19q13             *MYH14*         \[[@b139-gi-2018-16-4-e20], [@b140-gi-2018-16-4-e20]\]
  DFNA4B                19q13.32          *CEACAM16*      \[[@b142-gi-2018-16-4-e20]\]
  DFNA5                 7p15              *GSDME*         \[[@b144-gi-2018-16-4-e20], [@b145-gi-2018-16-4-e20]\]
  DFNA6                 4p16.3            *WFS1*          \[[@b148-gi-2018-16-4-e20]--[@b151-gi-2018-16-4-e20]\]
  DFNA7                 1q21-q23          *LMX1A*         \[[@b152-gi-2018-16-4-e20], [@b153-gi-2018-16-4-e20]\]
  DFNA8                 See DFNA12        \-              \-
  DFNA9                 14q12 q13         *COCH*          \[[@b157-gi-2018-16-4-e20], [@b158-gi-2018-16-4-e20]\]
  DFNA10                6q22 q23          *EYA4*          \[[@b160-gi-2018-16-4-e20], [@b161-gi-2018-16-4-e20]\]
  DFNA11                11q12.3 q21       *MYO7A*         \[[@b164-gi-2018-16-4-e20], [@b165-gi-2018-16-4-e20]\]
  DFNA12                11q2224           *TECTA*         \-
  DFNA13                6p21              *COL11A2*       \[[@b169-gi-2018-16-4-e20], [@b170-gi-2018-16-4-e20]\]
  DFNA14                See DFNA6         \-              \-
  DFNA15                5q31              *POU4F3*        \[[@b172-gi-2018-16-4-e20]\]
  DFNA16                2q24              Unknown         \[[@b174-gi-2018-16-4-e20]\]
  DFNA17                22q               *MYH9*          \[[@b176-gi-2018-16-4-e20], [@b177-gi-2018-16-4-e20]\]
  DFNA18                3q22              Unknown         \[[@b179-gi-2018-16-4-e20]\]
  DFNA19                10(pericentr.)    Unknown         \[[@b181-gi-2018-16-4-e20]\]
  DFNA20                17q25             *ACTG1*         \[[@b183-gi-2018-16-4-e20]--[@b185-gi-2018-16-4-e20]\]
  DFNA21                6p21              Unknown         \[[@b187-gi-2018-16-4-e20]\]
  DFNA22                6q13              *MYO6*          \[[@b189-gi-2018-16-4-e20]\]
  DFNA23                14q21 q22         *SIX1*          \[[@b191-gi-2018-16-4-e20], [@b192-gi-2018-16-4-e20]\]
  DFNA24                4q                Unknown         \[[@b194-gi-2018-16-4-e20]\]
  DFNA25                12q21 24          *SLC17A8*       \[[@b196-gi-2018-16-4-e20], [@b197-gi-2018-16-4-e20]\]
  DFNA26                See DFNA20        \-              \-
  DFNA27                4q12              *REST*          \[[@b199-gi-2018-16-4-e20], [@b200-gi-2018-16-4-e20]\]
  DFNA28                8q22              *GRHL2*         \[[@b202-gi-2018-16-4-e20]\]
  DFNA30                15q25 26          Unknown         \[[@b204-gi-2018-16-4-e20]\]
  DFNA31                6p21.3            Unknown         \[[@b206-gi-2018-16-4-e20]\]
  DFNA32                11p15             Unknown         \[[@b128-gi-2018-16-4-e20]\]
  DFNA33                13q34-qter        Unknown         \[[@b131-gi-2018-16-4-e20]\]
  DFNA34                1q44              *NLRP3*         \[[@b133-gi-2018-16-4-e20]\]
  DFNA36                9q13 q21          *TMC1*          \[[@b22-gi-2018-16-4-e20]\]
  DFNA37                1p21              *COL11A1*       \[[@b137-gi-2018-16-4-e20]\]
  DFNA38                See DFNA6         \-              \-
  DFNA39 (see note 1)   4q21.3            *DSPP*          \[[@b141-gi-2018-16-4-e20]\]
  DFNA40                16p12.2           *CRYM*          \[[@b143-gi-2018-16-4-e20]\]
  DFNA41                12q24-qter        *P2RX2*         \[[@b146-gi-2018-16-4-e20], [@b147-gi-2018-16-4-e20]\]
  DFNA42                5q31.1 q32        Unknown         \[[@b141-gi-2018-16-4-e20]\]
  DFNA43                2p12              Unknown         \[[@b154-gi-2018-16-4-e20]\]
  DFNA44                3q28 29           *CCDC50*        \[[@b155-gi-2018-16-4-e20], [@b156-gi-2018-16-4-e20]\]
  DFNA47                9p21 22           Unknown         \[[@b159-gi-2018-16-4-e20]\]
  DFNA48                12q13 q14         *MYO1A*         \[[@b162-gi-2018-16-4-e20], [@b163-gi-2018-16-4-e20]\]
  DFNA49                1q21 q23          Unknown         \[[@b166-gi-2018-16-4-e20]\]
  DFNA50                7q32.2            *MIRN96*        \[[@b167-gi-2018-16-4-e20], [@b168-gi-2018-16-4-e20]\]
  DFNA51                9q21              *TJP2*          \[[@b171-gi-2018-16-4-e20]\]
  DFNA52                4q28              Unknown         \[[@b141-gi-2018-16-4-e20]\]
  DFNA53                14q11.2 q12       Unknown         \[[@b173-gi-2018-16-4-e20]\]
  DFNA54                5q31              Unknown         \[[@b175-gi-2018-16-4-e20]\]
  DFNA56                9q31.3 q34.3      *TNC*           \[[@b178-gi-2018-16-4-e20]\]
  DFNA57                19p13.2           Unknown         \[[@b180-gi-2018-16-4-e20]\]
  DFNA58                2p12 p21          Unknown         \[[@b182-gi-2018-16-4-e20]\]
  DFNA59                11p14.2 q12.3     Unknown         \[[@b186-gi-2018-16-4-e20]\]
  DFNA60                2q21.3 q24.1      Unknown         \[[@b188-gi-2018-16-4-e20]\]
  DFNA64                12q24.31 q24.32   *SMAC/DIABLO*   \[[@b190-gi-2018-16-4-e20]\]
  DFNA65                16p13.3           *TBC1D24*       \[[@b193-gi-2018-16-4-e20]\]
  DFNA66                6q15 21           *CD164*         \[[@b195-gi-2018-16-4-e20]\]
  DFNA67                20q13.33          *OSBPL2*        \[[@b175-gi-2018-16-4-e20]\]
  DFNA68                15q25.2           *HOMER2*        \[[@b198-gi-2018-16-4-e20]\]
  DFNA69                12q21.32 q23.1    *KITLG*         \[[@b201-gi-2018-16-4-e20]\]
  DFNA70                3q21.3            *MCM2*          \[[@b203-gi-2018-16-4-e20]\]
  DFNA73                12q21.31          *PTPRQ*         \[[@b205-gi-2018-16-4-e20]\]

Note 1: Mutations in *DSPP* dentinogenesis imperfect associated with hearing impairment in some families.

Note 2: *MYO1A* has been called in to question as the causative gene for DFNA48 \[[@b207-gi-2018-16-4-e20]\].

###### 

Other non-syndromic hearing loss genes and loci according to Hereditary Hearing Loss Homepage

  Locus (OMIM)                                             Location     Gene (OMIM)   Key references (PubMed)
  -------------------------------------------------------- ------------ ------------- --------------------------------------------------------
  X-linked                                                                            
   DFNX1[a](#tfn7-gi-2018-16-4-e20){ref-type="table-fn"}   Xq22         *PRPS1*       \[[@b208-gi-2018-16-4-e20]\]
   DFNX2                                                   Xq21.1       *POU3F4*      \[[@b209-gi-2018-16-4-e20]\]
   DFNX3                                                   Xp21.2       Unknown       \[[@b210-gi-2018-16-4-e20], [@b211-gi-2018-16-4-e20]\]
   DFNX4                                                   Xp22         *SMPX*        \[[@b212-gi-2018-16-4-e20]\]
   DFNX5                                                   Xq26.1       *AIFM1*       \[[@b213-gi-2018-16-4-e20]\]
   DFNX6                                                   Xp22.3       *COL4A6*      \[[@b214-gi-2018-16-4-e20]\]
                                                                                      
  Y-linked                                                                            
   DFNY1                                                   Y            Unknown       \[[@b215-gi-2018-16-4-e20]\]
                                                                                      
  Modifier                                                                            
   DFNM1                                                   1q24         Unknown       \[[@b48-gi-2018-16-4-e20]\]
   DFNM2                                                   8q23         Unknown       \[[@b216-gi-2018-16-4-e20]\]
                                                                                      
  AUNA-Auditory                                            Neuropathy                 \[[@b217-gi-2018-16-4-e20], [@b218-gi-2018-16-4-e20]\]
   AUNA1                                                   13q14-21     *DIAPH3*      

Previous nomenclature designated X-linked loci as DFN but this has been changed to DFNX.

###### 

Syndromic hearing loss genes according to Hereditary Hearing Loss Homepage \[[@b6-gi-2018-16-4-e20]\]

  Gene (OMIM)                        Location       Inheritance                       Key references (PubMed)
  ---------------------------------- -------------- --------------------------------- --------------------------------------------------------
  Alport syndrome                                                                     
   *COL4A3*                          2q36.3         Autosomal recessive               \[[@b221-gi-2018-16-4-e20]\]
   *COL4A4*                          2q36.3         Autosomal recessive               \[[@b221-gi-2018-16-4-e20]\]
   *COL4A5*                          Xq22.3         X-linked recessive                \[[@b222-gi-2018-16-4-e20]\]
                                                                                      
  Branchio-Oto-Renal syndrome                                                         
   *EYA1*                            8q13.3         Autosomal dominant                \[[@b223-gi-2018-16-4-e20]\]
   *SIX5*                            19q13.32       Autosomal dominant                \[[@b224-gi-2018-16-4-e20]\]
   *SIX1*                            14q23.1        Autosomal dominant                \[[@b225-gi-2018-16-4-e20]\]
                                                                                      
  CHARGE syndrome                                                                     
   *SEMA3E*                          7q21.11        Autosomal dominant                \[[@b226-gi-2018-16-4-e20]\]
   *CHD7*                            8q12.2         Autosomal dominant                \[[@b227-gi-2018-16-4-e20]\]
                                                                                      
  Jervell & Lange-Nielsen syndrome                                                    
   *KNCQ1*                           11p15.5-15.4   Autosomal recessive               \[[@b228-gi-2018-16-4-e20]\]
   *KCNE1*                           21q22.12       Autosomal recessive               \[[@b229-gi-2018-16-4-e20], [@b230-gi-2018-16-4-e20]\]
                                                                                      
  Norrie disease                                                                      
   *NDP*                             Xp11.3         X-linked recessive                \[[@b231-gi-2018-16-4-e20], [@b232-gi-2018-16-4-e20]\]
                                                                                      
  Pendred syndrome                                                                    
   *SLC26A4*                         7q22.3         Autosomal recessive               \[[@b233-gi-2018-16-4-e20]\]
   *FOXI1*                           5q35.1         Autosomal recessive               \[[@b234-gi-2018-16-4-e20]\]
   *KCNJ10*                          1q23.2         Autosomal recessive               \[[@b235-gi-2018-16-4-e20]\]
                                                                                      
  Perrault syndrome                                                                   
   *HSD17B4*                         5q23.1         Autosomal recessive               \[[@b236-gi-2018-16-4-e20]\]
   *HARS2*                           5q31.3         Autosomal recessive               \[[@b236-gi-2018-16-4-e20]\]
   *CLPP*                            19p13.3        Autosomal recessive               \[[@b237-gi-2018-16-4-e20]\]
   *LARS2*                           3p21.31        Autosomal recessive               \[[@b238-gi-2018-16-4-e20]\]
   *TWNK*                            10q24.21       Autosomal recessive               \[[@b239-gi-2018-16-4-e20]\]
   *ERAL1*                           17q11.2        Autosomal recessive               \[[@b240-gi-2018-16-4-e20]\]
                                                                                      
  Stickler syndrome                                                                   
   *COL2A1*                          12q13.11       Autosomal dominant                \[[@b241-gi-2018-16-4-e20]\]
   *COL11A1*                         1p21           Autosomal dominant                \[[@b242-gi-2018-16-4-e20]\]
   *COL11A2*                         6p21.32        Autosomal recessive/dominant      \[[@b243-gi-2018-16-4-e20]\]
   *COL9A1*                          6q13           Autosomal recessive               \[[@b244-gi-2018-16-4-e20]\]
   *COL9A2*                          1p34.2         Autosomal recessive               \[[@b245-gi-2018-16-4-e20]\]
                                                                                      
  Treacher Collins syndrome                                                           
   *TCOF1*                           5q32-q33.1     Autosomal dominant                \[[@b246-gi-2018-16-4-e20]\]
   *POLR1D*                          13q12.2        Autosomal dominant                \[[@b247-gi-2018-16-4-e20]\]
   *POLR1C*                          6p21.1         Autosomal recessive               \[[@b247-gi-2018-16-4-e20]\]
                                                                                      
  Usher syndrome                                                                      
   *MYO7A*                           11q13.5        Autosomal recessive               \[[@b248-gi-2018-16-4-e20]\]
   *USH1C*                           11p15.1        Autosomal recessive               \[[@b249-gi-2018-16-4-e20]\]
   *CDH23*                           10q22.1        Autosomal recessive               \[[@b250-gi-2018-16-4-e20]\]
   *PCDH15*                          10q21.1        Autosomal recessive               \[[@b251-gi-2018-16-4-e20]\]
   *SANS/USH1G*                      17q25.1        Autosomal recessive               \[[@b252-gi-2018-16-4-e20]\]
   See Note A                        15q25.1        Autosomal recessive               \[[@b253-gi-2018-16-4-e20]\]
   *USH2A*                           1q41           Autosomal recessive               \[[@b254-gi-2018-16-4-e20]\]
   *ADGRV1/VLGR1/GPR98*              5q14.3         Autosomal recessive               \[[@b255-gi-2018-16-4-e20]\]
   *WHRN*                            9q32           Autosomal recessive               \[[@b256-gi-2018-16-4-e20]\]
   *CLRN1*                           3q25.1         Autosomal recessive               \[[@b257-gi-2018-16-4-e20]\]
                                                                                      
  Waardenburg syndrome                                                                
   *PAX3*                            2q36.1         Autosomal dominant                \[[@b258-gi-2018-16-4-e20]\]
   *MITF*                            3p13           Autosomal dominant                \[[@b259-gi-2018-16-4-e20]\]
   *SNAI2*                           8q11           Autosomal recessive               \[[@b260-gi-2018-16-4-e20]\]
   *SOX10*                           22q13.1        Autosomal dominant                \[[@b261-gi-2018-16-4-e20]\]
   *PAX3*                            2q36.1         Autosomal dominant or recessive   \[[@b262-gi-2018-16-4-e20]\]
   *EDNRB*                           13q22.3        Autosomal dominant or recessive   \[[@b263-gi-2018-16-4-e20]\]
   *EDN3*                            20q13.32       Autosomal dominant or recessive   \[[@b264-gi-2018-16-4-e20]\]
   *SOX10*                           22q13.1        Autosomal dominant                \[[@b265-gi-2018-16-4-e20]\]

###### 

Viral vectors used in gene therapy for genetic hearing loss studies

  Viral vector                     Example             Load         Animal                         Route of administration        Reference
  -------------------------------- ------------------- ------------ ------------------------------ ------------------------------ ------------------------------
  Adenovirus                       Ad5-CMV-Atoh1-GFP   Atoh1        Guinea pig                     Cochleostomy (scala media)     \[[@b274-gi-2018-16-4-e20]\]
  Ad5-CMV-Math1.11D                Math1               Guinea pig   Cochleostomy (scala media)     \[[@b275-gi-2018-16-4-e20]\]   
  Ad28-CMV-GFP + Ad28-GFAP-Atoh1   Atoh1               Mouse        Round window (scala tympani)   \[[@b278-gi-2018-16-4-e20]\]   
                                                                                                                                  
  Adeno-associated virus           AAV-mVGLUT3         VGLUT3       Mouse                          Round window (scala tympani)   \[[@b271-gi-2018-16-4-e20]\]
  AAV8-CMV-whirlin-GFP             WHRN                Mouse        Round window (scala tympani)   \[[@b272-gi-2018-16-4-e20]\]   
  AAV2/Anc80L65.CMV.trunc-harm     USH1C               Mouse        Round window (scala tympani)   \[[@b276-gi-2018-16-4-e20]\]   
  BAAV-*β*-actin-GFP               *β*-actin           Rat          Cochleostomy (scala media)     \[[@b279-gi-2018-16-4-e20]\]   
                                                                                                                                  
  Herpes simplex virus             pHSV-blc-2          BCL2         Rats                           Organ of Corti explants        \[[@b280-gi-2018-16-4-e20]\]
  pHSV-BDNF-LacZ                   BDNF                Rat          Spiral ganglia explant         \[[@b273-gi-2018-16-4-e20]\]   
                                                                                                                                  
  Lentivirus                       Lenti-HOX-GFP       GFP          Mouse                          Round window (scala tympani)   \[[@b277-gi-2018-16-4-e20]\]
  Lenti-WOX-GFP                                                                                                                   

###### 

Non-viral vectors used in gene therapy for genetic hearing loss studies

  Non-viral vector                  Example                         Load                                 Animal                            Route of administration                                  Reference
  --------------------------------- ------------------------------- ------------------------------------ --------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Cationic liposomes                Liposomes                       *β*-gal plasmid                      Guinea pig                        RWM after cochleostomy                                   \[[@b287-gi-2018-16-4-e20]\]
  Liposomes                         eGFP plasmid                    Mouse                                Gelfoam on RWM                    \[[@b288-gi-2018-16-4-e20]--[@b290-gi-2018-16-4-e20]\]   
  Lipofectamine 2000                Math1                           Rat                                  OC-derived cell line              \[[@b291-gi-2018-16-4-e20]\]                             
                                                                                                                                                                                                    
  Cationic non-liposomal polymers   Polybrene                       Integrin antisense oligonucleotide   Rats                              OC-derived cell line                                     \[[@b292-gi-2018-16-4-e20]\]
  Dendritic polymers (HPNP)         eGFP plasmid                    Rat                                  Sponge on RWM/cochlear explants   \[[@b293-gi-2018-16-4-e20]\]                             
  Polyethylenimine (PEI)            eGFP plasmid                    Guinea pig                           *Scala tympani* injection         \[[@b294-gi-2018-16-4-e20]\]                             
  PLGA nanoparticles                Fluorescent dye (Rhodamine)     Guinea pig                           Gelfoam on RWM                    \[[@b295-gi-2018-16-4-e20]\]                             
                                                                                                                                                                                                    
  Biolistic                         Gold particles using Gene gun   MyoXVa                               Mouse                             OC explants                                              \[[@b296-gi-2018-16-4-e20], [@b297-gi-2018-16-4-e20]\]
                                                                                                                                                                                                    
  Electroporation                   Electroporation                 Math1                                Rat                               OC explants                                              \[[@b298-gi-2018-16-4-e20], [@b299-gi-2018-16-4-e20]\]
  Electroporation                   Math1                           Mouse                                *In utero*                        \[[@b300-gi-2018-16-4-e20], [@b301-gi-2018-16-4-e20]\]   

RWM, round window membrane; eGFP, enhanced green fluorescent protein; OC, organ of Corti; PLGA, poly(lactic-co-glycolic acid).
